Good morning, you're tuned into Markets Desk.
Bristol Myers Squibb is turning heads in oncology after clinical data showed its cancer drug doubled progression-free survival time in patients. That is not incremental improvement — that is a step-change result, and with promising signals across other solid tumors, the pipeline implications for BMS are significant and investors are taking notice.
Shifting to Switzerland, Novartis posted a sharp drop in third-quarter profit, weighed down by an impairment charge and rising expenses, even as net sales continued to grow. The headline number stings, but management did lift its full-year two thousand twenty six core income outlook while holding firm on its sales guidance — a signal the underlying business remains on track.
And in social media, Reddit is making a compelling case for itself heading into two thousand twenty six. The platform delivered a net profit margin of twenty-four point one percent in fiscal two thousand twenty five alongside revenue growth approaching seventy percent — numbers that put it squarely in the conversation against peers like Snap and demand serious attention from growth-oriented investors.
That's the tape. Markets Desk, signing off the floor.
